GRCL — Gracell Biotechnologies Share News
0.000.00%
Last trade - 00:00- $972.69m
- $750.11m
Brief: Astrazeneca To Acquire Gracell, Furthering Cell Therapy Ambition Across Oncology And Autoimmune Diseases
Brief: Gracell Biotechnologies To Be Acquired By Astrazeneca, Furthering Cell Therapy Ambition Across Oncology And Autoimmune Diseases
Brief: Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F
CAR-T therapy developers fall amid U.S. FDA investigation
Brief: Gracell Announces FDA Clearance Of Application For Phase 1/2 Clinical Trial Of FasTCAR-T GC012F For Treatment Of Refractory Systemic Lupus Erythematosus
Brief: Gracell Biotechnologies Net Loss Attributable To Ordinary Shareholders For Three Months Ended September 30
Brief: Gracell Biotechnologies To Present Data Highlighting Preclinical Efficacy Of Smart Cart™
Gracell Bio rises after Stifel initiates coverage with 'buy'
Stifel initiates coverage on Gracell Biotechnologies with 'buy'
Brief: Gracell Biotechnologies Doses First Patient In Phase 1B/2 Clinical Trial
Brief: Gracell Biotechnologies Inc Files For Resale Of Up To 183.7 Million Ordinary Shares By The Selling Shareholders - SEC Filing
Brief: Ra Capital Management, L.P. Reports 9.99% Passive Stake In Gracell Biotechnologies - SEC Filing
Gracell Biotechnologies Inc reports results for the quarter ended in June - Earnings Summary
Brief: Gracell Biotechnologies Inc. Q2 net income RMB -146.9 million
Gracell Biotechnologies Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Gracell Biotechnologies Announces Up To $150 Million Private Placement Financing
Brief: Gracell Biotechnologies Presents Updated Data Of Deep And Durable Responses For Fastcar-T Gc012f
Gracell Biotechnologies Inc reports results for the quarter ended in March - Earnings Summary
Brief: Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F For Treatment Of Refractory Systemic Lupus Erythematosus (Sle)